Key clinical point: Excess exposure to steroids has a significant negative impact on patients with inflammatory bowel disease (IBD).
Major finding: Steroid excess was observed in 15% of patients. The risks for ≥1 hospitalizations for IBD (odds ratio [OR] 12.33; 95% CI 8.89-17.11) and infections (OR 2.89; 95% CI 1.82-4.61) and ≥1 courses of general practitioner-prescribed antibiotics (OR 1.41; 95% CI 1.07-1.86) were significantly higher in patients with steroid excess vs. those without steroid exposure.
Study details: Findings are from a retrospective study including 2246 patients with IBD and primary care information .
Disclosures: This study was supported by a research grant from AbbVie . T Raine and CP Selinger declared receiving research/educational grants or speaker/consultation fees from various sources, including AbbVie .
Source: Rosiou K et al. Sources of excess steroid prescriptions and clinical adverse outcomes associated with steroid excess in patients with inflammatory bowel disease: The Leeds IBD Steroids study. Aliment Pharmacol Ther. 2022 (May 24). Doi: 10.1111/apt.17039